Haleon executes tranche 2 buyback: 1,399,293 shares cancelled

Rhea-AI Filing Summary

Haleon plc announced the purchase and cancellation of 1,399,293 ordinary shares of
each under the second tranche of its share buyback programme announced 31 July 2025. Trades executed on 14 August 2025 on the London Stock Exchange/CBOE UK totalled 1,399,293 shares at an average price of 58.7136. After settlement, registered share capital is 8,974,906,495 ordinary shares, of which 3,880,205 are treasury shares, leaving 8,971,026,290 ordinary shares with voting rights for disclosure threshold purposes. A full trade breakdown is available via the provided RNS link and the company's investor website.

Insights

Securities Analyst

TL;DR: Small tranche of share buybacks executed and cancelled, modest reduction in outstanding voting stock; limited market impact.

The company executed 1,399,293 share purchases under the second tranche of its buyback programme, cancelling those shares. Relative to total registered capital of approximately 8.975 billion shares, this cancellation is immaterial in magnitude. The announcement fulfils transparency requirements by providing a trade breakdown and updated share counts for disclosure threshold calculations. No earnings, debt, or strategic acquisition details are included, so investor implications are limited to minor capital structure tightening.

Corporate Governance Expert

TL;DR: Transaction follows announced buyback programme; administrative update with compliance detail for shareholder reporting.

The filing documents settlement and cancellation mechanics and confirms the updated number of voting shares, which is useful for shareholders monitoring disclosure obligations. The availability of a detailed RNS trade breakdown and posting on the investor site aligns with market abuse regulation transparency requirements. This is a routine corporate action without indications of governance changes or material financial effects in the filing text.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	15 August 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

15 August 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 1,399,293 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	14 August 2025	14 August 2025	14 August 2025
Number of Shares purchased:	1,399,293	-	-
Highest price paid per Share (p):	360.4000	-	-
Lowest price paid per Share (p):	356.7000	-	-
Volume weighted average price paid per Share (p):	358.7136	-	-

Following the settlement of the above, the Company's registered share capital is 8,974,906,495 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,971,026,290 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/4286V_1-2025-8-14.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: August 15, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary